Hematogenous Osteomyelitis in Childhood Can Relapse Dozens of Years in Adulthood
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 37
- 试验地点
- 1
- 主要终点
- Rate of patients having an osteomyelitis
研究概览
简要总结
To our knowledge, few cases of relapse in adulthood are described in the literature except in patients with sickle cell disease and the epidemiological, clinical, laboratory, radiological features and the management of osteomyelitis relapsing in adulthood are not described. The aim of this retrospective multicentric cohort study : in France is to describe the epidemiological, clinical, laboratory, and radiological features and the management of adult patients who experienced a relapse between 2003-2015 of an acute hematogenous osteomyelitis acquired in the childhood (description of characterization of the period between the first episode of osteomyelitis and the second episode, description of signs of relapse and description of treatments used in the relapse). The data are analysed with non-comparative descriptive statistics.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult patients (≥ 18 years) who presented a relapse between 2003-2015 of a hematogenous osteomyelitis acquired in childhood.
- •the time limit between the 2 episodes must be at least 2 years
- •antecedent of osteomyelitis before 16 years
排除标准
- •inability to give the information to the patient
- •patients opposed to the use of their data
结局指标
主要结局
Rate of patients having an osteomyelitis
时间窗: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption
Description of the population
次要结局
- rate of management with surgery(Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption)
- rate of bacteria responsible for infection(Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption)
- Rate of Treatment Failure(Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption)